Enhanced PKC beta II translocation and PKC beta II-RACK1 interactions in PKC epsilon-induced heart failure: a role for RACK1.
Recent investigations have established a role for the beta II-isoform of protein kinase C (PKC beta II) in the induction of cardiac hypertrophy and failure. Although receptors for activated C kinase (RACKs) have been shown to direct PKC signal transduction, the mechanism through which RACK1, a selective PKC beta II RACK, participates in PKC beta II-mediated cardiac hypertrophy and failure remains undefined. We have previously reported that PKC epsilon activation modulates the expression of RACKs, and that altered epsilon-isoform of PKC (PKC epsilon)-RACK interactions may facilitate the genesis of cardiac phenotypes in mice. Here, we present evidence that high levels of PKC epsilon activity are commensurate with impaired left ventricular function (dP/dt = 6,074 +/- 248 mmHg/s in control vs. 3,784 +/- 269 mmHg/s in transgenic) and significant myocardial hypertrophy. More importantly, we demonstrate that high levels of PKC epsilon activation induce a significant colocalization of PKC beta II with RACK1 (154 +/- 7% of control) and a marked redistribution of PKC beta II to the particulate fraction (17 +/- 2% of total PKC beta II in control mice vs. 49 +/- 5% of total PKC beta II in hypertrophied mice), without compensatory changes of the other eight PKC isoforms present in the mouse heart. This enhanced PKC beta II activation is coupled with increased RACK1 expression and PKC beta II-RACK1 interactions, demonstrating PKC epsilon-induced PKC beta II signaling via a RACK1-dependent mechanism. Taken together with our previous findings regarding enhanced RACK1 expression and PKC epsilon-RACK1 interactions in the setting of cardiac hypertrophy and failure, these results suggest that RACK1 serves as a nexus for at least two isoforms of PKC, the epsilon-isoform and the beta II-isoform, thus coordinating PKC-mediated hypertrophic signaling.
Pass
J M
JM
Department of Physiology and Biophysics, University of Louisville, Louisville, Kentucky 40202, USA.
Gao
J
J
Jones
W K
WK
Wead
W B
WB
Wu
X
X
Zhang
J
J
Baines
C P
CP
Bolli
R
R
Zheng
Y T
YT
Joshua
I G
IG
Ping
P
P
D000199:Actins / Q000235:genetics; D000818:Animals; D006332:Cardiomegaly / Q000378:metabolism; D015870:Gene Expression / Q000502:physiology; D006333:Heart Failure / Q000378:metabolism*; D006801:Humans; D007527:Isoenzymes / Q000235:genetics* / Q000378:metabolism*; D019169:Jurkat Cells; D051379:Mice; D008822:Mice, Transgenic; D016296:Mutagenesis / Q000502:physiology; D009200:Myocardial Contraction / Q000502:physiology; D009206:Myocardium / Q000201:enzymology*; D018995:Myosin Heavy Chains / Q000235:genetics; D010455:Peptides / Q000378:metabolism*; D025941:Protein Interaction Mapping; D011493:Protein Kinase C / Q000235:genetics* / Q000378:metabolism*; D064546:Protein Kinase C beta; D051744:Protein Kinase C-epsilon; D000075370:Receptors for Activated C Kinase; D015398:Signal Transduction / Q000502:physiology
D000199:Actins; D007527:Isoenzymes; D010455:Peptides; D000075370:Receptors for Activated C Kinase; C070301:peptide I; C497256:Prkce protein, mouse; C497255:PRKCE protein, human; D011493:Protein Kinase C; D064546:Protein Kinase C beta; D051744:Protein Kinase C-epsilon; D018995:Myosin Heavy Chains